Neuralstem Inc. (NASDAQ:CUR)‘s stock had its “buy” rating reissued by analysts at Roth Capital in a research report issued on Friday. They currently have a $1.20 price target on the stock. Roth Capital’s price objective would indicate a potential upside of 287.10% from the company’s previous close.
Separately, Brean Capital reiterated a “buy” rating and issued a $4.00 price target on shares of Neuralstem in a research note on Monday, September 12th.
Neuralstem (NASDAQ:CUR) traded up 1.935% during midday trading on Friday, hitting $0.316. The company had a trading volume of 670,061 shares. Neuralstem has a 12-month low of $0.19 and a 12-month high of $1.96. The stock’s market cap is $36.26 million. The company’s 50 day moving average is $0.27 and its 200 day moving average is $0.43.
Neuralstem (NASDAQ:CUR) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The business earned $2.50 million during the quarter, compared to the consensus estimate of $2.50 million. Neuralstem had a negative return on equity of 574.32% and a negative net margin of 173,849.97%. On average, equities analysts anticipate that Neuralstem will post ($0.17) EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the stock. Blair William & Co. IL bought a new position in shares of Neuralstem during the second quarter worth approximately $122,000. Sabby Management LLC bought a new position in shares of Neuralstem during the second quarter worth approximately $1,893,000. Finally, Vanguard Group Inc. increased its position in shares of Neuralstem by 21.8% in the second quarter. Vanguard Group Inc. now owns 3,384,138 shares of the company’s stock worth $984,000 after buying an additional 606,500 shares during the last quarter. Institutional investors own 18.20% of the company’s stock.
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.